Literature DB >> 976190

Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria.

S C Cheng, K Suzuki, W Sadee, B W Harding.   

Abstract

Effects of spironolactone, canrenone and canrenoate-K on adrenal cytochrome P450 (P450) and corticosteroid biosynthesis were examined by studying difference spectra, P450 reduction and corticoid hydroxylation in mitochondrial preparations isolated from zona fasciculata and zona glomerulosa of bovine adrenals and from adrenal adenoma and hyperplastic adrenal cortex removed from patients with hyperaldosteronism. All three agents bound to P450 producing type I difference spectra and underwent hydroxylation. They all inhibited 11beta-hydroxylation in bovine adrenal at 30 muM and higher concentrations. Canrenone, the most potent inhibitor, blocked enzyme activity by 60% at a concentration of 60 muM. Spironolactone stimulated P450 reduction. The order of potency of inhibition was found to correlate with the order of affinity of these agents for P450. 11beta-Hydroxylase in human adrenal appeared to be less sensitive to canrenone. All three agents or their hydroxylated metabolites blocked 18-hydroxylation in bovine adrenal at lower concentrations. Canrenoate-K, being the most effective, inhibited 52% at 20 muM. Low concentrations of canrenone (2.5-5.0 muM) were without effect on 11beta-hydroxylase but markedly inhibited 18-hydroxylation (62-76%) in hyperplastic human adrenals. The inhibitors produced mixed type inhibition of 11beta-hydroxylation and competitive type inhibition of 18-hydroxylation. These findings indicate that at low concentrations spironolactone and its major metabolites, canrenone and canrenoate-K, or their hydroxylated metabolites, can directly interfere with the biosynthesis of aldosterone in bovine and certain human adrenal cortical tissue.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 976190     DOI: 10.1210/endo-99-4-1097

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  15 in total

Review 1.  Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Drug Metab Rev       Date:  2018-08       Impact factor: 4.518

2.  A comparison of some extra-renal effects of spironolactone and canrenone.

Authors:  G J Huston; E A Al-Dujaili
Journal:  Br J Clin Pharmacol       Date:  1979-04       Impact factor: 4.335

3.  Interference of spironolactone therapy with adrenal steroid metabolism in secondary hyperaldosteronism.

Authors:  U Abshagen; S Spörl; M Schöneshöfer; M L'age; W Oelkers
Journal:  Klin Wochenschr       Date:  1978-04-01

4.  Influence of spironolactone on serum corticosteroids in primary hyperaldosteronism.

Authors:  U Abshagen; S Spörl; W Oelkers
Journal:  Klin Wochenschr       Date:  1979-02-15

5.  Influence of spironolactone on neonatal screening for congenital adrenal hyperplasia.

Authors:  I Terai; K Yamano; N Ichihara; J Arai; K Kobayashi
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-11       Impact factor: 5.747

6.  Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects.

Authors:  J A Millar; R Fraser; P Mason; B Leckie; A M Cumming; J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

7.  Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis.

Authors:  P Ye; T Yamashita; D M Pollock; H Sasano; W E Rainey
Journal:  Horm Metab Res       Date:  2008-09-25       Impact factor: 2.936

8.  Non-interaction of spironolactone medication and cortisol metabolism in man.

Authors:  U Abshagen; S Spörl; M L'age
Journal:  Klin Wochenschr       Date:  1978-02-01

9.  Spironolactone bodies in aldosteronomas and in the attached adrenals. Enzyme histochemical study of 19 cases of primary aldosteronism and a case of aldosteronism due to bilateral diffuse hyperplasia of the zona glomerulosa.

Authors:  M Aiba; H Suzuki; K Kageyama; M Murai; H Tazaki; O Abe; T Saruta
Journal:  Am J Pathol       Date:  1981-06       Impact factor: 4.307

Review 10.  Effects of antihypertensive drugs on endocrine function.

Authors:  E P Brass
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.